Tarsus (TARS) Q2 2026 Earnings Call Transcript

Tarsus (TARS) held its Q2 2026 earnings call on Aug. 6, 2026, with management focused on XDEMVY commercial performance and an acquisition pipeline update. Net product sales for XDEMVY reached $173.9 million in the quarter, representing 69% year-over-year growth and 20% growth versus Q1 2026. Full-year 2026 revenue guidance for XDEMVY net product sales was raised to $685 million–$705 million, up from $670 million–$700 million. The company also agreed to acquire Alkeus Pharmaceuticals for $450 million upfront ($270 million cash and $180 million stock) for ALK-001. Cash stood at $449.7 million as of June 30, 2026, with $125 million raised via private placement.